Graft-versus-host disease.
Graft-versus-host disease.
复制标题
DOI：
10.1016/s0140-6736(09)60237-3
复制
发表时间：
2009-05-02
期刊：
影响因子：
168.9
通讯作者：
Holler, Ernst
中科院分区：
文献类型：
--
作者：
Ferrara, James L. M.;Levine, John E.;Reddy, Pavan;Holler, Ernst
造血细胞移植(HCT)是一种强化疗法，用于治疗高危血液系统恶性疾病和其他危及生命的血液系统和遗传性疾病。HCT的主要并发症是移植物抗宿主病(GVHD)，这是一种影响许多器官系统的免疫疾病，包括胃肠道、肝脏、皮肤和肺。患有这一并发症的患者数量继续增加，许多人在接受HCT后从移植中心返回家中，需要继续使用免疫抑制药物进行治疗，这增加了他们发生严重感染和其他并发症的风险。在本次研讨会中，我们回顾了我们对GHVD的危险因素和原因、与其病理生理学有关的细胞和细胞因子网络的理解，以及目前预防和治疗该疾病的策略。我们还总结了支持性护理措施，这些措施对于管理这些医疗脆弱的人口是必不可少的。
Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. The main complication of HCT is graft-versus-host disease (GVHD), an immunological disorder that affects many organ systems, including the gastrointestinal tract, liver, skin, and lungs. The number of patients with this complication continues to grow, and many return home from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that increases their risks for serious infections and other complications. In this Seminar, we review our understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease. We also summarise supportive-care measures that are essential for management of this medically fragile population.